Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Gains from Sales and Divestitures (2017)

Historic Gains from Sales and Divestitures for Summit Therapeutics (SMMT) over the last 1 years, with Q4 2017 value amounting to $18.59.

  • Summit Therapeutics' Gains from Sales and Divestitures changed N/A to $18.59 in Q4 2017 from the same period last year, while for Dec 2017 it was $18.59, marking a year-over-year change of. This contributed to the annual value of $18.59 for FY2017, which is N/A changed from last year.
  • Per Summit Therapeutics' latest filing, its Gains from Sales and Divestitures stood at $18.59 for Q4 2017.
  • Summit Therapeutics' Gains from Sales and Divestitures' 5-year high stood at $18.59 during Q4 2017, with a 5-year trough of $18.59 in Q4 2017.